A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

Also called NCT07030101

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
EMS (from the registry)
Registry
  • NCT NCT07030101
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07030101. Randomized; triple masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension
Acronym
TRÍADE-HA
Condition
Hypertension
Intervention (Drug)
TCA108
Intervention (Drug)
Bramicar HCT
Intervention (Drug)
Micardis Anlo
Lead sponsor
EMS (class: industry)

Record details

Record id
cardio:ct-nct07030101
Content hash
f147b3cb328a71dd0148c283cce5f38ae34a2232196605217105417bd8098da2